Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Beam Therapeutics Inc’s current trading price is -48.35% away from its 52-week high, while its distance from the 52-week low is 57.23%. The stock’s price range during this period has varied between $16.95 and $51.60. The company, active in the Healthcare sector, saw a trading volume of around 0.74 million for the day, considerably lower average daily volume of 1.15 million observed over the last three months.
Beam Therapeutics Inc (BEAM) has a current stock price of $26.65. During the previous trading session, the stock witnessed a notable rise, reaching a high of $25.33 after opening at $25.26. The stock’s low for the day was $24.18, and it eventually closed at $24.79.
Beam Therapeutics Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $51.60 on 12/13/22, and the lowest price during that time was $16.95, recorded on 10/23/23.
How Financial Performance Impacts Market Capitalization
Beam Therapeutics Inc (BEAM) has experienced a quarterly rise of 12.45% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.17B and boasts a workforce of 507 employees.
Decoding Analysts’ Ratings for Beam Therapeutics Inc
As of right now, 9 analysts are rating Beam Therapeutics Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 25.15, with a change in price of -6.68. Similarly, Beam Therapeutics Inc recorded 1,051,539 in trading volume during the last 100 days, posting a change of -20.18%.
How BEAM’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for BEAM stands at 0.22. Similarly, the long-term debt-to-equity ratio is also 0.21.
BEAM Stock Stochastic Average
As of today, the raw stochastic average of Beam Therapeutics Inc over the last 50 days is at 94.83%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 97.37%. Further, the company’s Stochastic %K and %D values for the last 20 days were 90.26% and 86.40%, respectively.
BEAM Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price loss of -31.86% this year. Over the last six months, there has been a stronger performance of -22.84%. The price of BEAM fallen by 45.15% during the last 30 days period. For the last 5-days stocks have improved 20.26%.